These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29989303)

  • 1. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.
    Wu XY; Hu YB; Li HJ; Wan B; Zhang CX; Zhang B; Hu H; Zhang Q; Lv TF; Zhan P; Song Y
    J Cell Mol Med; 2018 Sep; 22(9):4328-4334. PubMed ID: 29989303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer].
    Peng Y; Wang Y; Li J; Hao X; Hu X
    Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):590-4. PubMed ID: 27666548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer.
    Huang Z; Xu D; Zhang F; Ying Y; Song L
    Clin Transl Oncol; 2016 Oct; 18(10):1019-25. PubMed ID: 26886220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective application of neuroendocrine markers in the diagnosis and treatment of small cell lung cancer.
    Du J; Li Y; Wang L; Zhou Y; Shen Y; Xu F; Chen Y
    Clin Chim Acta; 2020 Oct; 509():295-303. PubMed ID: 32592711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
    Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
    Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
    Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
    Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
    [No Abstract]   [Full Text] [Related]  

  • 8. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC).
    Shibayama T; Ueoka H; Nishii K; Kiura K; Tabata M; Miyatake K; Kitajima T; Harada M
    Lung Cancer; 2001 Apr; 32(1):61-9. PubMed ID: 11282430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer.
    Kim HR; Oh IJ; Shin MG; Park JS; Choi HJ; Ban HJ; Kim KS; Kim YC; Shin JH; Ryang DW; Suh SP
    J Korean Med Sci; 2011 May; 26(5):625-30. PubMed ID: 21532852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic and prognostic value of ProGRP in lung cancer.
    Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
    Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the diagnostic and prognostic value of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer.
    Li L; Zhang Q; Wang Y; Xu C
    J Clin Lab Anal; 2023 Apr; 37(7):e24865. PubMed ID: 37088873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
    Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China.
    Korse CM; Holdenrieder S; Zhi XY; Zhang X; Qiu L; Geistanger A; Lisy MR; Wehnl B; van den Broek D; Escudero JM; Standop J; Hu M; Molina R
    Clin Chim Acta; 2015 Jan; 438():388-95. PubMed ID: 25262909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
    Liu X; Zhang W; Yin W; Xiao Y; Zhou C; Hu Y; Geng S
    Medicine (Baltimore); 2017 Nov; 96(46):e8258. PubMed ID: 29145241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement.
    Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T
    Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test.
    Muley T; Zhang X; Holdenrieder S; Korse CM; Zhi XY; Molina R; Liu Z; Hartmann G; van den Heuvel MM; Qian K; Marrades R; Engel C; He Y; Wehnl B; Dayyani F; Herth F
    Tumour Biol; 2020 Sep; 42(9):1010428320958603. PubMed ID: 32964798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
    Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
    Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
    Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
    Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
    Schneider J; Philipp M; Salewski L; Velcovsky HG
    Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.